[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461307":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Washington","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"N. gonorrhea (gyrA wildtype) -Ciprofloxacin Treatment Arm","EXPERIMENTAL","Participants who are N. gonorrhea (NG) positive and gyrA WT, will receive ciprofloxacin 500 mg PO x 1.",[13],"Drug: Ciprofloxacin 500 mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ciprofloxacin 500 mg","Ciprofloxacin 500 MG, taken once orally.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Lindley Barbee, MD, MPH","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Angela LeClair","CONTACT","206-744-0489","achein@uw.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Public Health -- Seattle & King County Sexual Health Clinic","RECRUITING","Seattle","Washington","98104","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-122.33207,47.60621,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":20,"phoneExt":20,"email":20},"Angela LeClair, ND",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Lindley Barbee","Associate Professor: School of Medicine Allergy and Infectious Diseases","100461307","speedx-ciprofloxacin-gyra-assay-for-n-gonorrhoeae-gonococcal-infection-100461307",false,"NCT05286931","SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection","Evaluation of SpeeDx's Ciprofloxacin gyrA Assay for Clinical Care of STD Clinic Patients With Neisseria Gonorrhea","Inclusion Criteria:\n\n* English speaking\n* Have access to the internet (via computer or phone) on at least a weekly basis\n* Asymptomatic (as defined below)\n\nExclusion Criteria:\n\n* Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment.\n* Antibiotic use within the last 2 weeks\n* Contact to syphilis\n* Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return\n* Anyone receiving a gonococcal-active drug (such as Doxycycline, Penicillin, Ceftriaxone) during the visit. Those receiving metronidazole, fluconazole, or clotrimazole will not be excluded.\n* Known allergy to ciprofloxacin and\u002For ceftriaxone",true,"ALL","18 Years",{"count":63,"type":64},1800,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.",[70],"Neisseria Gonorrhoeae Infection",[72,73,74],"antimicrobial resistance","ciprofloxacin","molecular diagnostics","2022-03-09",{"date":77,"type":78},"2022-03-18","ACTUAL",{"date":80,"type":78},"2022-03-03",{"date":82,"type":64},"2026-12-31",{"name":5,"class":6},1]